TSE:OPS Opsens (OPS) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free OPS Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$2.85▼C$2.9052-Week Range N/AVolume49,783 shsAverage Volume112,402 shsMarket CapitalizationC$335.47 millionP/E RatioN/ADividend YieldN/APrice TargetC$2.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider Trades Get Opsens alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Opsens Stock (TSE:OPS)Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for cardiovascular interventions. The company operates in two segments, Medical and Industrial. The company provides advanced optical-based pressure guidewire (OptoWire), a guidewire used in the transcatheter aortic valve replacement procedure; and a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated in other medical devices. It also develops, manufactures, and markets medical products; and offers OPP-GD fiber optic differential pressure sensors and the OEC fiber optic extensometer sensors. The company serves life sciences, energy, defense and aerospace, geotechnical, civil engineering, scientific laboratory, and various other markets. The company sells its products through a network of distributors and direct sales force in the United States, Japan, Canada, and internationally. Opsens Inc. was formerly known as Capital DCB inc. and changed its name to OpSens Inc. in October 2006. The company was founded in 2003 and is headquartered in Québec, Canada. As of December 12, 2023, Opsens Inc. operates as a subsidiary of Haemonetics Corporation.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> OPS Stock News HeadlinesApril 12, 2024 | markets.businessinsider.comHaemonetics Poised for Growth with Strong Q4 Projections and Strategic AcquisitionsMarch 6, 2024 | seekingalpha.comHaemonetics Corporation: Improved Performance, Another Bolt-On DealApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 9, 2024 | finance.yahoo.comHaemonetics Corporation (NYSE:HAE) Q3 2024 Earnings Call TranscriptFebruary 3, 2024 | theglobeandmail.comClosing Bell: Opsens Inc flat on Wednesday (OPS)December 8, 2023 | finance.yahoo.comOPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICSDecember 1, 2023 | finance.yahoo.comOPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICSNovember 28, 2023 | ca.finance.yahoo.comHill, Opsens, Thinkific at 52-Week High on NewsApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.November 28, 2023 | finance.yahoo.comOPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIEDNovember 28, 2023 | theglobeandmail.comOpsens: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (OPS)November 22, 2023 | msn.comOpsens GAAP EPS of -C$0.01, revenue of C$14.11MNovember 22, 2023 | finance.yahoo.comOPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTSNovember 13, 2023 | finance.yahoo.comINDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATIONNovember 5, 2023 | morningstar.comOpsens Inc OPSOctober 14, 2023 | theglobeandmail.comClosing Bell: Opsens Inc flat on Friday (OPS)October 12, 2023 | theglobeandmail.comClosing Bell: Opsens Inc flat on Thursday (OPS)October 11, 2023 | markets.businessinsider.comRBC Capital Believes Opsens Inc (OPS) Won’t Stop HereOctober 10, 2023 | marketwatch.comOpsens Shares Climb on C$345M Deal to be Acquired by HaemoneticsOctober 5, 2023 | msn.comOpsens (OPSSF) Price Target Increased by 6.28% to 2.77August 21, 2023 | cnbc.comRBC names the Canadian stocks set to ‘materially outperform’ in the next 12 months — here are 8 on its conviction listAugust 8, 2023 | markets.businessinsider.comNyra Medical names Lori Chmura as Chief Executive OfficerJuly 14, 2023 | markets.businessinsider.comOpsens Inc (OPS) Receives a Buy from RBC CapitalJuly 13, 2023 | finance.yahoo.comMorning News Call - Canada, July 13July 13, 2023 | marketwatch.comOpsens 3Q Loss Widens as Sales, Marketing Costs Rise, Revenue Tops ViewsJuly 13, 2023 | finance.yahoo.comOPSENS ANNOUNCES A THIRD CONSECUTIVE QUARTER OF RECORD REVENUES FOR THIRD QUARTER FISCAL 2023July 12, 2023 | markets.businessinsider.comOpsens is about to announce its earnings — here's what Wall Street expectsSee More Headlines Receive OPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opsens and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/29/2017Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolTSE:OPS CUSIPN/A CIKN/A Webopsens.com Phone418-781-0333FaxN/AEmployees293Year FoundedN/APrice Target and Rating Average Stock Price TargetC$2.90 High Stock Price TargetC$2.90 Low Stock Price TargetC$2.90 Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-12,400,000.00 Net Margins-25.65% Pretax MarginN/A Return on Equity-36.43% Return on Assets-15.76% Debt Debt-to-Equity Ratio27.22 Current Ratio4.42 Quick Ratio3.56 Sales & Book Value Annual SalesC$48.35 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow8.68 Book ValueC$0.29 per share Price / BookN/AMiscellaneous Outstanding Shares115,680,000Free FloatN/AMarket CapC$335.47 million OptionableNot Optionable Beta0.32 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Alan W. Milinazzo (Age 63)Executive Chairman of the Board Comp: $99.2kMr. Louis Laflamme C.A.CPA, CPA, CEO, President & DirectorMr. Brad DavisChief Commercial OfficerMr. John HanniganChief Financial OfficerMr. Pierre PoulinCorporate ControllerKey CompetitorsCRH MedicalTSE:CRHZentekCVE:ZENDialogue Health TechnologiesTSE:CAREFennec PharmaceuticalsTSE:FRXProMetic Life SciencesTSE:PLIView All Competitors OPS Stock Analysis - Frequently Asked Questions Should I buy or sell Opsens stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Opsens in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OPS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPS, but not buy additional shares or sell existing shares. View OPS analyst ratings or view top-rated stocks. What is Opsens' stock price target for 2024? 1 brokers have issued twelve-month price objectives for Opsens' shares. Their OPS share price targets range from C$2.90 to C$2.90. On average, they predict the company's stock price to reach C$2.90 in the next twelve months. View analysts price targets for OPS or view top-rated stocks among Wall Street analysts. How were Opsens' earnings last quarter? Opsens Inc. (TSE:OPS) issued its earnings results on Thursday, June, 29th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The firm had revenue of $4.89 million for the quarter. Opsens had a negative net margin of 25.65% and a negative trailing twelve-month return on equity of 36.43%. What other stocks do shareholders of Opsens own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opsens investors own include Acadian Timber (ADN), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC), Barrick Gold (ABX) and Absolute Software Co. (ABT.TO) (ABT). How do I buy shares of Opsens? Shares of OPS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:OPS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opsens Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.